Search results
Merck (MRK) Gets CHMP Nod for Keytruda in Adjuvant Lung Cancer
Zacks via Yahoo Finance· 8 months agoMerck's (MRK) Keytruda gets a positive CHMP opinion, recommending the approval of the drug for the...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 12 hours agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda...
Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA
Zacks via Yahoo Finance· 2 years agoThe FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA...
After Shelving Two Keytruda Trials, Merck Touts Encouraging Data From Keytruda Regime Study In Lung...
Benzinga via Yahoo Finance· 1 year agoMerck & Co Inc's (NYSE: MRK) Phase 3 KEYNOTE-671 trial investigating Keytruda met one of its dual...
Advanced Lung Cancer and Immunotherapy
Verywell Health via Yahoo News· 8 months agoImmunotherapy is a newer class of treatment for lung and other cancers. It primes the body’s natural immune system to fight back against cancer....
Five-Year Data For Merck's Keytruda Plus Chemo Shows Sustained Survival Benefit In Lung Cancer...
Benzinga via Yahoo Finance· 2 years agoMerck & Co Inc (NYSE: MRK) Keytruda plus chemotherapy demonstrated a survival benefit and durable...
The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed
Investor's Business Daily· 2 years agoShares of MRTX stock rocketed Tuesday after Mirati Therapeutics unveiled early — but promising —...
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoMerck MRK boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor, Keytruda,...
Merck's lung cancer drug combo fails trial in setback for new therapy class
Reuters via AOL· 5 months agoMerck's experimental anti-TIGIT drug vibostolimab in combination with its approved therapy Keytruda...
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
Zacks via Yahoo Finance· 8 months agoGilead Sciences, Inc. GILD announced encouraging data from the mid-stage study evaluating its breast...